ReviewHistopathology2022
WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.
Review in Histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Approach and nomenclature problems of extracutaneous basaloid neoplasias of visceral organs with three cases of basaloid carcinoma described for the first time in the urinary bladder.Histology and histopathology · 2026Article
- Primary adenoid cystic carcinoma (basal cell type) of the prostate: a case report.Discover oncology · 2026Article
- Explainable and visualizable machine learning model development and validation for 5-year postoperative survival prediction in prostate cancer patients aged ≥ 65 years.BMC geriatrics · 2026Article
- Cervical Lymphadenopathy as Initial Presentation of Foamy Gland Adenocarcinoma of the Prostate: A Case Report.OncoTargets and therapy · 2026Article
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- The Evaluation of Diagnostic, Prognostic, and Predictive Role of Hematologic Inflammatory Indices NLR, PLR, and LMR in Common Solid Tumors.Cancer reports (Hoboken, N.J.) · 2025Review
- International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.The American journal of surgical pathology · 2025Article
- Prostate carcinoma in core biopsy : Diagnostic criteria, mimics/pitfalls, subtypes.Pathologie (Heidelberg, Germany) · 2025Review
- [Prostate cancer in the biopsy : Diagnostic criteria, mimickers/pitfalls, and subtypes].Pathologie (Heidelberg, Germany) · 2025Review
- Exploring the impact of cuproptosis on prostate cancer prognosisFrontiers in pharmacology · 2025Article
- Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.Frontiers in oncology · 2025Article
- Signet-ring cell carcinoma in rectal malignancies: a case report with an unexpected outcome.Frontiers in oncology · 2025Article
- Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.Oncology reviews · 2025Review
- Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects.Asian journal of andrology · 2024Review
- Prostate cancer treatment recommendation study based on machine learning and SHAP interpreter.Cancer science · 2024Article
- Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.Journal of cellular and molecular medicine · 2024Article
- Role of NOncology reports · 2024Review
- Treatment-induced neuroendocrine prostate cancer andWorld journal of clinical cases · 2024Article
- Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.American journal of clinical and experimental urology · 2024Article
- Artificial intelligence in pathologic diagnosis, prognosis and prediction of prostate cancer.American journal of clinical and experimental urology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The fifth edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems encompasses several updates to the classification and diagnosis of prostatic carcinoma as well as incorporating advancements in the assessment of its prognosis, including recent grading modifications. Some of the salient aspects include: (1) recognition that prostatic intraepithelial neoplasia (PIN)-like carcinoma is not synonymous with a pattern of ductal carcinoma, but better classified as a subtype of acinar adenocarcinoma; (2) a specific section on treatment-related neuroendocrine prostatic carcinoma in view of the tight correlation between androgen deprivation therapy and the development of prostatic carcinoma with neuroendocrine morphology, and the emerging data on lineage plasticity; (3) a terminology change of basal cell carcinoma to "adenoid cystic (basal cell) cell carcinoma" given the presence of an underlying MYB::NFIB gene fusion in many cases; (4) discussion of the current issues in the grading of acinar adenocarcinoma and the prognostic significance of cribriform growth patterns; and (5) more detailed coverage of intraductal carcinoma of prostate (IDC-P) reflecting our increased knowledge of this entity, while recommending the descriptive term atypical intraductal proliferation (AIP) for lesions falling short of IDC-P but containing more atypia than typically seen in high-grade prostatic intraepithelial neoplasia (HGPIN). Lesions previously regarded as cribriform patterns of HGPIN are now included in the AIP category. This review discusses these developments, summarising the existing literature, as well as the emerging morphological and molecular data that underpins the classification and prognostication of prostatic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.